Yeungnam Univ J Med.  2021 Jan;38(1):65-69. 10.12701/yujm.2020.00269.

Development of donepezil-induced hypokalemia following treatment of cognitive impairment

Affiliations
  • 1Division of Nephrology, Department of Internal Medicine, Incheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
  • 2Division of Nephrology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea

Abstract

Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.

Keyword

Alzheimer disease; Cognitive dysfunction; Donepezil; Hypokalemia

Figure

  • Fig. 1. Abdominal computed tomography scan. (A) Both adrenal glands (arrows) show no abnormalities. (B) Both kidneys (arrows) show no abnormal findings.

  • Fig. 2. Summary of serum potassium level, potassium supplementation, total intake, and total output per day. IV, intravenous; PO, per oral.


Reference

References

1. Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant. 2007; 22:3471–7.
Article
2. Widodo D, Setiawan B, Chen K, Nainggolan L, Santoso WD. The prevalence of hypokalemia in hospitalized patients with infectious diseases problem at Cipto Mangunkusumo Hospital, Jakarta. Acta Med Indones. 2006; 38:202–5.
3. Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol. 2011; 7:75–84.
Article
4. Paltiel O, Salakhov E, Ronen I, Berg D, Israeli A. Management of severe hypokalemia in hospitalized patients: a study of quality of care based on computerized databases. Arch Intern Med. 2001; 161:1089–95.
Article
5. Li HC, Luo KX, Wang JS, Wang QX. Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: a case report. Medicine (Baltimore). 2020; 99:e19443.
6. Arai H, Hashimoto N, Sumitomo K, Takase T, Ishii M. Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: Japan-Great Outcome of Long-term trial with Donepezil (J-GOLD). Psychogeriatrics. 2018; 18:402–11.
Article
7. Cubeddu LX. Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev. 2016; 12:141–54.
Article
8. Manzo C, Putignano S. Drug-induced lupus erythematosus associated with donepezil: a case report. Age Ageing. 2015; 44:1062–3.
Article
9. US Food and Drug Administration (FDA). Highlights of prescribing information: Aricept [Internet]. Silver Spring (MD): FDA;2012. [cited 2020 Feb 20]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf.
10. eHealthMe. Will you have hypokalemia with Donepezil? (a study of FDA data) [Internet]. eHealthMe;2020. [cited 2020 Feb 20]. https://www.ehealthme.com/ds/donepezil/hypokalemia/.
11. Li XL, Hu N, Tan MS, Yu JT, Tan L. Behavioral and psychological symptoms in Alzheimer's disease. Biomed Res Int. 2014; 2014:927804.
Article
12. Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol. 2005; 1:527–36.
Article
13. Dunn NR, Pearce GL, Shakir SA. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol. 2000; 14:406–8.
Article
14. Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer's disease. Br J Clin Pharmacol. 2004; 58(Suppl 1):1–8.
Article
15. Tabish M, Mahendran M, Ray A, Vikram NK. Colistin-induced acquired Bartter-like syndrome: an unusual cause of meltdown. BMJ Case Rep. 2020; 13:e232630.
Article
16. Min HK, Kim EO, Lee SJ, Chang YK, Suh KS, Yang CW, et al. Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis. BMC Nephrol. 2013; 14:13.
Article
Full Text Links
  • YUJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr